Sanofi announced a lawsuit against Novo Nordisk in the United States over a dispute over drug information

Source: Ding Xiangyuan 2016-12-30 French pharmaceutical company Sanofi filed a lawsuit in the New Jersey District Court on December 23, accusing Novo Nordisk of publishing false information that Sanofi's insulin drugs will no longer be applicable to many American patients, thereby promoting the sale of its competing products Sanofi asked Novo Nordisk to pay damages in an unknown amount and withdraw marketing materials of its drug tresiba According to Sanofi, the marketing material encourages doctors and patients to switch from Sanofi's products Lantus and toujeo (for diabetes) to tresiba, on the grounds that Sanofi's drugs will be "blocked" by CVS Caremark, an American pharmacy revenue management company, in January Novo Nord has yet to comment Sanofi said CVS is replacing its product with a cheaper version of Eli Lilly's similar drug, basaglar, to add to its so-called standard formulary, the list of drugs covered by the Medicare program Although many health insurance plans do not use CVS's standard formula, and some may still include Sanofi's drugs, patients will have to pay more, Sanofi said, adding that if the insurance does not include its products, companies can help individuals purchase drugs "We believe that Novo Nordisk's statement on whether CVS Caremark covers Lantus and toujeo's prescriptions will have a false statement and misleading effect on the continued availability of Lantus and toujeo," a Sanofi spokesman said in an email statement Lantus and toujeo are two diabetes drugs sold by Sanofi in the United States, the world's largest medical market Pressure on the US diabetes business has been rising in recent months as CVs and the insurance company United Health Group announced plans to replace Lantus and toujeo with basaglar Sanofi reported better than expected quarterly results in October and raised its earnings forecast for the year However, French pharmaceutical companies insist on their prediction that the average annual sales revenue of diabetes business after currency adjustment will decrease by 4% to 8% from 2015 to 2018.